COVID-19 Disease and Coagulopathy: Assessment of Clotting Factor Levels in Patients With SARS-CoV-2 Infection

September 27, 2021 updated by: Liontos Angelos, University Hospital, Ioannina
Effect of Covid-19 disease in clotting factors levels in hospitalized patients

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Effect of Covid-19 disease in clotting factors levels in hospitalized patients positive for sars-cov2 infection.

Association between clotting factors levels and disease severity,morbidity and mortality in these patients.

Effect of anticoagulant therapy in the clotting factors' levels in these patients

Study Type

Observational

Enrollment (Actual)

50

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Greece
    • Epirus
      • Ioánnina, Epirus, Greece, 45500
        • University General Hospital of Ioannina

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

ALL ELIGIBLE PATIENTS AS DEFINED BY CRITERIA

Description

Inclusion Criteria:

  • AGE> 18
  • SINGED INFORMED CONSENT FORM
  • POSITIVE PCR TEST FOR SARS-COV2 INFECTION
  • FINDINGS IN CXR OR CT OF THE LUNGS CONSISTENT WITH INFECTION OF LOWER RESPIRATORY TRACT

Exclusion Criteria:

  • AGE<18
  • DENIAL TO PROVIDE INFORMED CONSENT FORM
  • HISTORY OF MALIGNANCY
  • PRIOR USE OF ANTICOAGULANT THERAPY
  • PRIOR USE OF STEROIDS LONGER THAN 14 DAYS
  • LACTATION-PREGNANCY

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
EFFECT OF COVID-19 DISEASE IN CLOTTING FACTORS
Time Frame: 6 MONTHS
leves of cloting factors before and after treatment with LMWH
6 MONTHS

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Ioannina

Collaborators

INTERNAL MEDICINE DEPARTMENT, 1ST WARD

Investigators

  • Principal Investigator: HARALAMPOS MILIONIS, PROFESSOR, University General Hospital of Ioannina

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 23, 2020

Primary Completion (Actual)

May 23, 2021

Study Completion (Actual)

June 23, 2021

Study Registration Dates

First Submitted

March 4, 2021

First Submitted That Met QC Criteria

March 5, 2021

First Posted (Actual)

March 8, 2021

Study Record Updates

Last Update Posted (Actual)

September 28, 2021

Last Update Submitted That Met QC Criteria

September 27, 2021

Last Verified

September 1, 2021

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 895/23-12-2020

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe